{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:11:54Z","timestamp":1781478714113,"version":"3.54.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T00:00:00Z","timestamp":1726358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T00:00:00Z","timestamp":1726358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Development Program of China","award":["No.2019YFA0111600"],"award-info":[{"award-number":["No.2019YFA0111600"]}]},{"name":"Development Program of China","award":["No.2019YFE0120800"],"award-info":[{"award-number":["No.2019YFE0120800"]}]},{"name":"Key Program of National Natural Science Foundation of China","award":["82130090"],"award-info":[{"award-number":["82130090"]}]},{"name":"Key Program of National Natural Science Foundation of China","award":["U22A20329"],"award-info":[{"award-number":["U22A20329"]}]},{"name":"Science Found for Creative Research Groups of the National Natural Science Foundation of China","award":["82221002"],"award-info":[{"award-number":["82221002"]}]},{"name":"Central South University Research Program of Advanced Interdisciplinary Studies","award":["2023QYJC004"],"award-info":[{"award-number":["2023QYJC004"]}]},{"name":"the Natural Science Foundation of China for outstanding Young Scholars","award":["No.82022060"],"award-info":[{"award-number":["No.82022060"]}]},{"name":"The science and technology innovation Program of Hunan Province","award":["2022RC3004"],"award-info":[{"award-number":["2022RC3004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"DOI":"10.1186\/s40246-024-00651-3","type":"journal-article","created":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T14:02:10Z","timestamp":1726408930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Integrated multiomics revealed adenosine signaling predict immunotherapy response and regulate tumor ecosystem of melanoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Yantao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poyee","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanxiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,15]]},"reference":[{"key":"651_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.Cd-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-1059.","journal-title":"Cancer Discov"},{"key":"651_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology Nature reviews. Drug Discov. 2022;21:141\u201362. https:\/\/doi.org\/10.1038\/s41573-021-00339-6.","journal-title":"Drug Discov"},{"key":"651_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016;23:27\u201347. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.006.","journal-title":"Cell Metab"},{"key":"651_CR4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrc.2017.110","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nature reviews. Cancer. 2017;17:765. https:\/\/doi.org\/10.1038\/nrc.2017.110.","journal-title":"Cancer"},{"key":"651_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","volume":"6","author":"RD Leone","year":"2018","unstructured":"Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6:57. https:\/\/doi.org\/10.1186\/s40425-018-0360-8.","journal-title":"J Immunother Cancer"},{"key":"651_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nri.2016.4","volume":"16","author":"C Cekic","year":"2016","unstructured":"Cekic C, Linden J. Purinergic regulation of the immune system. Nature reviews. Immunology. 2016;16:177\u201392. https:\/\/doi.org\/10.1038\/nri.2016.4.","journal-title":"Immunology"},{"key":"651_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.imlet.2018.03.007","volume":"205","author":"E Ferretti","year":"2019","unstructured":"Ferretti E, Horenstein AL, Canzonetta C, Costa F, Morandi F. Canonical and non-canonical adenosinergic pathways. Immunol Lett. 2019;205:25\u201330. https:\/\/doi.org\/10.1016\/j.imlet.2018.03.007.","journal-title":"Immunol Lett"},{"key":"651_CR8","doi-asserted-by":"publisher","first-page":"932","DOI":"10.4049\/jimmunol.173.2.932","volume":"173","author":"H Zhang","year":"2004","unstructured":"Zhang H, et al. Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3\u2019,5\u2019-monophosphate and phosphatases. J Immunol (Baltimore, Md: 1950). 2004;173:932\u201344. https:\/\/doi.org\/10.4049\/jimmunol.173.2.932.","journal-title":"J Immunol (Baltimore, Md.: 1950)"},{"key":"651_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/eji.200425524","volume":"35","author":"S Minguet","year":"2005","unstructured":"Minguet S, et al. Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur J Immunol. 2005;35:31\u201341. https:\/\/doi.org\/10.1002\/eji.200425524.","journal-title":"Eur J Immunol"},{"key":"651_CR10","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1182\/blood-2010-06-290643","volume":"116","author":"KL Wallace","year":"2010","unstructured":"Wallace KL, Linden J. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood. 2010;116:5010\u201320. https:\/\/doi.org\/10.1182\/blood-2010-06-290643.","journal-title":"Blood"},{"key":"651_CR11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1096\/fj.201700770R","volume":"32","author":"B Cs\u00f3ka","year":"2018","unstructured":"Cs\u00f3ka B, et al. Adenosine receptors differentially regulate type 2 cytokine production by IL-33-activated bone marrow cells, ILC2s, and macrophages. FASEB J. 2018;32:829\u201337. https:\/\/doi.org\/10.1096\/fj.201700770R.","journal-title":"FASEB J"},{"key":"651_CR12","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1182\/bloodadvances.2019000176","volume":"3","author":"MD Hazenberg","year":"2019","unstructured":"Hazenberg MD, et al. Human ectoenzyme-expressing ILC3: immunosuppressive innate cells that are depleted in graft-versus-host disease. Blood Adv. 2019;3:3650\u201360. https:\/\/doi.org\/10.1182\/bloodadvances.2019000176.","journal-title":"Blood Adv"},{"key":"651_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-004089","volume":"10","author":"RC Augustin","year":"2022","unstructured":"Augustin RC, et al. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer. 2022;10:1. https:\/\/doi.org\/10.1136\/jitc-2021-004089.","journal-title":"J Immunother Cancer"},{"key":"651_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","volume":"18","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nature reviews. Cancer. 2018;18:601\u201318. https:\/\/doi.org\/10.1038\/s41568-018-0037-0.","journal-title":"Cancer"},{"key":"651_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","volume":"22","author":"C Xia","year":"2023","unstructured":"Xia C, Yin S, To KKW, Fu L. CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol Cancer. 2023;22:44. https:\/\/doi.org\/10.1186\/s12943-023-01733-x.","journal-title":"Mol Cancer"},{"key":"651_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/annonc\/mdx730","volume":"29","author":"L Buisseret","year":"2018","unstructured":"Buisseret L, et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. Ann Oncol. 2018;29:1056\u201362. https:\/\/doi.org\/10.1093\/annonc\/mdx730.","journal-title":"Ann Oncol"},{"key":"651_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/1078-0432.Ccr-15-1181","volume":"22","author":"BG Leclerc","year":"2016","unstructured":"Leclerc BG, et al. CD73 expression is an independent prognostic factor in prostate cancer. Clin Cancer Res. 2016;22:158\u201366. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1181.","journal-title":"Clin Cancer Res"},{"key":"651_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2020-001467","volume":"8","author":"A Tripathi","year":"2020","unstructured":"Tripathi A, et al. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. J Immunother Cancer. 2020;8:1. https:\/\/doi.org\/10.1136\/jitc-2020-001467.","journal-title":"J Immunother Cancer"},{"key":"651_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.trecan.2016.01.003","volume":"2","author":"L Antonioli","year":"2016","unstructured":"Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Hask\u00f3 G. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer. 2016;2:95\u2013109. https:\/\/doi.org\/10.1016\/j.trecan.2016.01.003.","journal-title":"Trends Cancer"},{"key":"651_CR20","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1158\/0008-5472.Can-13-3583","volume":"74","author":"C Cekic","year":"2014","unstructured":"Cekic C, Day YJ, Sag D, Linden J. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res. 2014;74:7250\u20139. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-3583.","journal-title":"Cancer Res"},{"key":"651_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nature reviews. Clin Oncol. 2020;17:611\u201329. https:\/\/doi.org\/10.1038\/s41571-020-0382-2.","journal-title":"Clin Oncol"},{"key":"651_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/carcin\/bgy154","volume":"40","author":"MK Koivisto","year":"2019","unstructured":"Koivisto MK, et al. Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. Carcinogenesis. 2019;40:84\u201392. https:\/\/doi.org\/10.1093\/carcin\/bgy154.","journal-title":"Carcinogenesis"},{"key":"651_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s42255-019-0045-8","volume":"1","author":"Y Ye","year":"2019","unstructured":"Ye Y, et al. Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nat Metab. 2019;1:431\u201344. https:\/\/doi.org\/10.1038\/s42255-019-0045-8.","journal-title":"Nat Metab"},{"key":"651_CR24","doi-asserted-by":"publisher","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","volume":"49","author":"D Sun","year":"2021","unstructured":"Sun D, et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucl Acids Res. 2021;49:D1420-d1430. https:\/\/doi.org\/10.1093\/nar\/gkaa1020.","journal-title":"Nucl Acids Res"},{"key":"651_CR25","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41587-021-00935-2","volume":"39","author":"E Zhao","year":"2021","unstructured":"Zhao E, et al. Spatial transcriptomics at subspot resolution with BayesSpace. Nat Biotechnol. 2021;39:1375\u201384. https:\/\/doi.org\/10.1038\/s41587-021-00935-2.","journal-title":"Nat Biotechnol"},{"key":"651_CR26","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucl Acids Res. 2015;43:e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucl Acids Res"},{"key":"651_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14:7. https:\/\/doi.org\/10.1186\/1471-2105-14-7.","journal-title":"BMC Bioinf"},{"key":"651_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004.","journal-title":"Cell Syst"},{"key":"651_CR29","doi-asserted-by":"publisher","unstructured":"G. Korotkevich, V. S., A. Sergushichev. Fast gene set enrichment analysis. bioRxiv (2019). https:\/\/doi.org\/10.1101\/060012","DOI":"10.1101\/060012"},{"key":"651_CR30","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.xinn.2021.100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Cambridge (Mass)). 2021;2:1041. https:\/\/doi.org\/10.1016\/j.xinn.2021.100141.","journal-title":"Innovation (Cambridge (Mass.))"},{"key":"651_CR31","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.Can-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108\u201310. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-0307.","journal-title":"Cancer Res"},{"key":"651_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:220. https:\/\/doi.org\/10.1186\/s13059-017-1349-1.","journal-title":"Genome Biol"},{"key":"651_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-1-0716-0327-7_17","volume":"2120","author":"J Racle","year":"2020","unstructured":"Racle J, Gfeller D. EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data. Methods in molecular biology (Clifton, NJ). 2020;2120:233\u201348. https:\/\/doi.org\/10.1007\/978-1-0716-0327-7_17.","journal-title":"Methods in molecular biology (Clifton, NJ)"},{"key":"651_CR34","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https:\/\/doi.org\/10.1038\/ncomms3612.","journal-title":"Nat Commun"},{"key":"651_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218. https:\/\/doi.org\/10.1186\/s13059-016-1070-5.","journal-title":"Genome Biol"},{"key":"651_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","volume":"11","author":"F Finotello","year":"2019","unstructured":"Finotello F, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019;11:34. https:\/\/doi.org\/10.1186\/s13073-019-0638-6.","journal-title":"Genome Med"},{"key":"651_CR37","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/jci91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340. https:\/\/doi.org\/10.1172\/jci91190.","journal-title":"J Clin Invest"},{"key":"651_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science (New York, NY). 2018;362:1. https:\/\/doi.org\/10.1126\/science.aar3593.","journal-title":"Science (New York, N.Y.)"},{"key":"651_CR39","unstructured":"Johnson, K. S. phenoptr: inForm Helper Functions. R package version 0.3.2 (2022)."},{"key":"651_CR40","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573\u201387. https:\/\/doi.org\/10.1016\/j.cell.2021.04.048.","journal-title":"Cell"},{"key":"651_CR41","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon L, et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018;175:984\u201397. https:\/\/doi.org\/10.1016\/j.cell.2018.09.006.","journal-title":"Cell"},{"key":"651_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (New York, NY). 2016;352:189\u201396. https:\/\/doi.org\/10.1126\/science.aad0501.","journal-title":"Science (New York, N.Y.)"},{"key":"651_CR43","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, et al. Inference and analysis of cell-cell communication using Cell Chat. Nat Commun. 2021;12:1088. https:\/\/doi.org\/10.1038\/s41467-021-21246-9.","journal-title":"Nat Commun"},{"key":"651_CR44","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1038\/s41467-020-18873-z","volume":"11","author":"R Hou","year":"2020","unstructured":"Hou R, Denisenko E, Ong HT, Ramilowski JA, Forrest ARR. Predicting cell-to-cell communication networks using NATMI. Nat Commun. 2020;11:5011. https:\/\/doi.org\/10.1038\/s41467-020-18873-z.","journal-title":"Nat Commun"},{"key":"651_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41592-019-0667-5","volume":"17","author":"R Browaeys","year":"2020","unstructured":"Browaeys R, Saelens W, Saeys Y. NicheNet: modeling intercellular communication by linking ligands to target genes. Nat Methods. 2020;17:159\u201362. https:\/\/doi.org\/10.1038\/s41592-019-0667-5.","journal-title":"Nat Methods"},{"key":"651_CR46","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ccell.2019.10.007","volume":"36","author":"D Boison","year":"2019","unstructured":"Boison D, Yegutkin GG. Adenosine metabolism: emerging concepts for cancer therapy. Cancer Cell. 2019;36:582\u201396. https:\/\/doi.org\/10.1016\/j.ccell.2019.10.007.","journal-title":"Cancer Cell"},{"key":"651_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/cyto.b.21092","volume":"84","author":"V Quarona","year":"2013","unstructured":"Quarona V, et al. CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytomet B Clin Cytom. 2013;84:207\u201317. https:\/\/doi.org\/10.1002\/cyto.b.21092.","journal-title":"Cytomet B Clin Cytom"},{"key":"651_CR48","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2174\/138945012800564095","volume":"13","author":"L Antonioli","year":"2012","unstructured":"Antonioli L, et al. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr Drug Targets. 2012;13:842\u201362. https:\/\/doi.org\/10.2174\/138945012800564095.","journal-title":"Curr Drug Targets"},{"key":"651_CR49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrd1983","volume":"5","author":"KA Jacobson","year":"2006","unstructured":"Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5:247\u201364. https:\/\/doi.org\/10.1038\/nrd1983.","journal-title":"Nat Rev Drug Discov"},{"key":"651_CR50","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/ijc.29047","volume":"136","author":"K Jayawardana","year":"2015","unstructured":"Jayawardana K, et al. Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. Int J Cancer. 2015;136:863\u201374. https:\/\/doi.org\/10.1002\/ijc.29047.","journal-title":"Int J Cancer"},{"key":"651_CR51","doi-asserted-by":"publisher","first-page":"20429","DOI":"10.1073\/pnas.0905139106","volume":"106","author":"D Bogunovic","year":"2009","unstructured":"Bogunovic D, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. 2009;106:20429\u201334. https:\/\/doi.org\/10.1073\/pnas.0905139106.","journal-title":"Proc Natl Acad Sci USA"},{"key":"651_CR52","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1158\/1078-0432.Ccr-09-2509","volume":"16","author":"G J\u00f6nsson","year":"2010","unstructured":"J\u00f6nsson G, et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res. 2010;16:3356\u201367. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-2509.","journal-title":"Clin Cancer Res"},{"key":"651_CR53","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017;171:934-949.e916. https:\/\/doi.org\/10.1016\/j.cell.2017.09.028.","journal-title":"Cell"},{"key":"651_CR54","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide TN, et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy. Cancer Cell. 2019;35:238\u201355. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.003.","journal-title":"Cancer Cell"},{"key":"651_CR55","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.1158\/0008-5472.Can-18-0747","volume":"78","author":"K Thrane","year":"2018","unstructured":"Thrane K, Eriksson H, Maaskola J, Hansson J, Lundeberg J. Spatially resolved transcriptomics enables dissection of genetic heterogeneity in stage III cutaneous malignant melanoma. Cancer Res. 2018;78:5970\u20139. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-0747.","journal-title":"Cancer Res"},{"key":"651_CR56","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ncb3333","volume":"18","author":"GP Nader","year":"2016","unstructured":"Nader GP, Ezratty EJ, Gundersen GG. FAK, talin and PIPKI\u03b3 regulate endocytosed integrin activation to polarize focal adhesion assembly. Nat Cell Biol. 2016;18:491\u2013503. https:\/\/doi.org\/10.1038\/ncb3333.","journal-title":"Nat Cell Biol"},{"key":"651_CR57","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1158\/0008-5472.Can-09-3761","volume":"70","author":"B Garmy-Susini","year":"2010","unstructured":"Garmy-Susini B, et al. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res. 2010;70:3042\u201351. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-3761.","journal-title":"Cancer Res"},{"key":"651_CR58","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/0008-5472.Can-13-0602","volume":"73","author":"LM Knowles","year":"2013","unstructured":"Knowles LM, et al. Integrin \u03b1v\u03b23 and fibronectin upregulate Slug in cancer cells to promote clot invasion and metastasis. Cancer Res. 2013;73:6175\u201384. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-0602.","journal-title":"Cancer Res"},{"key":"651_CR59","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1158\/0008-5472.Can-09-3312","volume":"70","author":"G Malik","year":"2010","unstructured":"Malik G, et al. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res. 2010;70:4327\u201334. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-3312.","journal-title":"Cancer Res"},{"key":"651_CR60","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jhep.2021.06.023","volume":"75","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, et al. Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer. J Hepatol. 2021;75:1128\u201341. https:\/\/doi.org\/10.1016\/j.jhep.2021.06.023.","journal-title":"J Hepatol"},{"key":"651_CR61","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13046-018-0814-3","volume":"37","author":"J Lu","year":"2018","unstructured":"Lu J, et al. Exosomal miR-9 inhibits angiogenesis by targeting MDK and regulating PDK\/AKT pathway in nasopharyngeal carcinoma. J Experim Clin Cancer Res. 2018;37:147. https:\/\/doi.org\/10.1186\/s13046-018-0814-3.","journal-title":"J Experim Clin Cancer Res"},{"key":"651_CR62","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/cr.2013.158","volume":"24","author":"D Jia","year":"2014","unstructured":"Jia D, et al. Amplification of MPZL1\/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma. Cell Res. 2014;24:204\u201317. https:\/\/doi.org\/10.1038\/cr.2013.158.","journal-title":"Cell Res"},{"key":"651_CR63","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.7150\/ijbs.68776","volume":"18","author":"D Sun","year":"2022","unstructured":"Sun D, et al. LncRNA TNFRSF10A-AS1 promotes gastric cancer by directly binding to oncogenic MPZL1 and is associated with patient outcome. Int J Biol Sci. 2022;18:3156\u201366. https:\/\/doi.org\/10.7150\/ijbs.68776.","journal-title":"Int J Biol Sci"},{"key":"651_CR64","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ccell.2022.06.011","volume":"40","author":"Y Chen","year":"2022","unstructured":"Chen Y, et al. Oncogenic collagen I homotrimers from cancer cells bind to \u03b13\u03b21 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell. 2022;40:818\u201334. https:\/\/doi.org\/10.1016\/j.ccell.2022.06.011.","journal-title":"Cancer Cell"},{"key":"651_CR65","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"D Chowell","year":"2018","unstructured":"Chowell D, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359:582\u20137. https:\/\/doi.org\/10.1126\/science.aao4572.","journal-title":"Science"},{"key":"651_CR66","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/cmi.2017.161","volume":"15","author":"K Prajapati","year":"2018","unstructured":"Prajapati K, Perez C, Rojas LBP, Burke B, Guevara-Patino JA. Functions of NKG2D in CD8(+) T cells: an opportunity for immunotherapy. Cell Mol Immunol. 2018;15:470\u20139. https:\/\/doi.org\/10.1038\/cmi.2017.161.","journal-title":"Cell Mol Immunol"},{"key":"651_CR67","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.Cd-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger S, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7:1420\u201335. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0593.","journal-title":"Cancer Discov"},{"key":"651_CR68","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1172\/jci46322","volume":"121","author":"M Jeansson","year":"2011","unstructured":"Jeansson M, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest. 2011;121:2278\u201389. https:\/\/doi.org\/10.1172\/jci46322.","journal-title":"J Clin Invest"},{"key":"651_CR69","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13045-021-01192-1","volume":"14","author":"J Xiong","year":"2021","unstructured":"Xiong J, et al. Integrins regulate stemness in solid tumor: an emerging therapeutic target. J Hematol Oncol. 2021;14:177. https:\/\/doi.org\/10.1186\/s13045-021-01192-1.","journal-title":"J Hematol Oncol"},{"key":"651_CR70","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3389\/fimmu.2018.02203","volume":"9","author":"P Macor","year":"2018","unstructured":"Macor P, Capolla S, Tedesco F. Complement as a biological tool to control tumor growth. Front Immunol. 2018;9:2203. https:\/\/doi.org\/10.3389\/fimmu.2018.02203.","journal-title":"Front Immunol"},{"key":"651_CR71","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.4049\/jimmunol.1401082","volume":"194","author":"MH Nelson","year":"2015","unstructured":"Nelson MH, et al. The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol. 2015;194:1737\u201347. https:\/\/doi.org\/10.4049\/jimmunol.1401082.","journal-title":"J Immunol"},{"key":"651_CR72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Ann Rev Immunol. 2013;31:51\u201372. https:\/\/doi.org\/10.1146\/annurev-immunol-032712-100008.","journal-title":"Ann Rev Immunol"},{"key":"651_CR73","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev. 2017;276:121\u201344. https:\/\/doi.org\/10.1111\/imr.12528.","journal-title":"Immunol Rev"},{"key":"651_CR74","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41586-022-04974-w","volume":"607","author":"R de Reuver","year":"2022","unstructured":"de Reuver R, et al. ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation. Nature. 2022;607:784\u20139. https:\/\/doi.org\/10.1038\/s41586-022-04974-w.","journal-title":"Nature"},{"key":"651_CR75","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tips.2021.10.010","volume":"43","author":"L Antonioli","year":"2022","unstructured":"Antonioli L, Pacher P, Hask\u00f3 G. Adenosine and inflammation: it\u2019s time to (re)solve the problem. Trends Pharmacol Sci. 2022;43:43\u201355. https:\/\/doi.org\/10.1016\/j.tips.2021.10.010.","journal-title":"Trends Pharmacol Sci"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-024-00651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-024-00651-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-024-00651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T14:07:54Z","timestamp":1726409274000},"score":1,"resource":{"primary":{"URL":"https:\/\/humgenomics.biomedcentral.com\/articles\/10.1186\/s40246-024-00651-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,15]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1186\/s40246-024-00651-3","relation":{},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,15]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All tissue samples were obtained in compliance with informed consent policy. The study protocol was approved by the Institutional Review Board and ethics committee of Xiangya Hospital, Central South University. Clinical information is summarized in Table S2. All procedures were performed in compliance with relevant laws and institutional guidelines and have been approved by the appropriate institutional committees. Informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}